Senti Biosciences, Inc.

Dynamics Special Purpose Corp (Nasdaq: DYNS), a life sciences-focused blank-check company, completed its initial public offering in 2021 and filed an amended quarterly report on December 10, 2021, during its active de-SPAC process. The vehicle announced a business combination with Senti Biosciences, Inc., a synthetic biology firm developing programmable gene circuit medicines targeting oncology and other disease areas; the merger subsequently closed, bringing Senti Biosciences to public markets. The 10-Q/A amendment, accession number 0001193125-21-353981, reflects disclosure updates filed during the combination period. For full filing history, sponsor details, and real-time SPAC analytics on DYNS and thousands of other vehicles, sign up for complete access at SpacDesk.